B
rain tumours known as malignant gliomas are almost always lethal. Indeed, this cancer is the leading cause of braintumour-related death in children and adults 1 . Despite tremendous advances in understanding the cell biology and genomics underlying glioma development and progression, patient survival rates have remained stagnant, and few effective therapies exist. Venkatesh et al. 2 reveal on page 533 that a protein secreted from nonmalignant brain cells in the microenvironment surrounding the tumour can be therapeutically targeted. Such intervention might offer a fundamentally new approach to glioma treatment.
Standard therapy for malignant glioma often combines surgical tumour removal, radiation treatment and chemotherapy. Since the start of the twentieth century, a meagre three therapies have been approved for the treatment of malignant gliomas [3] [4] [5] . Dozens of clinical trials testing targeted therapies for gliomas have failed over the past two decades, despite being based on sound scientific rationales. The development of new therapies is hampered by the diversity of glioma cells in different patients, as well as the paucity of easily targetable mutations in most such cells.
Current understanding about the interaction between glioma cells and their microenvironment in the central nervous system is limited, particularly with regard to the activity of their neighbouring neurons. Although it is known that the electrical activity of neurons in the brain shapes normal brain development, many questions remain about how the proliferation and growth of glioma cells are governed by electrical stimuli in neurons and neuronal activity.
Gliomas arise from non-neuronal, glial cells. Venkatesh and colleagues have previously shown 6,7 that neuronal activity promotes the growth of glial cells in vivo in mice 6 and, through a series of in vitro and in vivo experiments, demonstrated that, in response to neuronal activity, neurons secrete a portion of the protein Nlgn3 that promotes glioma growth and proliferation 7 . Venkatesh et al. began the present study by investigating the signalling pathways mediating the glioma-supporting effects of secreted Nlgn3 in mice. They found that a key event is the phosphorylation of the kinase enzyme FAK in glioma cells, a modification that results in the activation of downstream signalling targets that include the proteins SRC, PI3K, mTOR and MAPK.
To try to translate their observations of this system into possible therapeutic options, Venkatesh and colleagues used mice containing mutations in certain genes and pharmacological tools to disrupt the signalling between the microenvironment and the cancer ous cells. They also transplanted samples of human gliomas into immuno deficient mice that do not reject human tissue, a technique known as xenografting.
Consistent with their hypothesis that secreted Nlgn3 mediates microenvironmental support driven by neuronal activity, the authors found that these transplanted glioma cells can grow in the brains of mice that express wild-type Nlgn3, but not in the brains of mice lacking Nlgn3. This Nlgn3-dependent difference in tumour growth was less prominent in the initial establishment of the tumour, and more pronounced in later stages of growth. However, when the authors transplanted samples of human breast cancer that had migrated to grow in the brain, these tumour cells did not exhibit Nlgn3-dependent growth differences, suggesting that the role of Nlgn3 in the microenvironment is specific to glioma, rather than a general mechanism that affects any type of tumour growing in the brain.
Nlgn3 is expressed on the surface of non-malignant cells surrounding the tumour, and is secreted and cleaved in response to neuronal electrical activity 7 . Venkatesh and colleagues identified the enzyme responsible for this cleavage by searching for enzymes that cleave proteins at amino acid sites that match the cleavage pattern observed for Nlgn3. The enzyme Adam10 has the expected cleavage capacity, and when the authors tested its role using drugs that inhibit it, the secretion of Nlgn3 from neurons grown in vitro was diminished or prevented. Pharmacological inhibition of Adam10 had no direct effect on the in vitro 9 . These inhibitors could potentially be repurposed to treat individuals with malignant glioma. This approach would not have been immediately obvious from results using existing tools that identify potential biological targets for therapy, such as in vitro highthroughput drug screening. These tools are normally used to test whether drugs can limit the growth of cancer cells in vitro rather than whether they can inhibit interactions between cancer cells and their non-cancerous neighbours. However, some malignant gliomas treated with ADAM10 inhibitors in vivo in this study in mice showed a reduction in tumour growth, but not complete tumour destruction, suggesting that this type of therapy will probably need to be combined with other approaches.
NEWS & VIEWS
In considering the unique physiology of the brain microenvironment, Venkatesh and colleagues offer a new approach to treating malignant gliomas by focusing on the surrounding cells. Most of the current targeted therapies for malignant gliomas are applicable to only a small subset of patients, but the idea of interrupting the molecular support that the glioma receives from its normal microenvironment raises the possibility of targeting a diverse range of glioma subtypes and patient ages. Rather than approaching the daunting glioma 'monster' head-on, clinicians might instead consider an indirect approach of 'draining the swamp' around the malignant cells (Fig. 1) .
Such an environmental-blockade strategy might, in addition to the approach outlined by Venkatesh and colleagues, also include the inhibition of other microenvironmental factors that promote tumour growth. For example, combination therapies might also target the immunosuppressive environment of tumour cells that blunts the body's immune response targeting the tumour, or they might inhibit factors that aid the formation of tumour blood vessels. Such combinations could lead to improved outcomes that are urgently needed for these patients. ■ 
Michael D. Taylor is in the Division of Neurosurgery and

Evaporating planetesimals
Two studies show that evaporation of molten rock was intrinsic to the formation of Earth and other rocky bodies in the Solar System, suggesting that violent collisions played a key part in the formation process. See Letters p.507 & p.511
T he concentrations of elements in meteorites called chondrites are thought to reflect the chemistry of the early Solar System -an idea reinforced by the fact that chondrites have a similar composition to that of the Sun. However, Earth and comparable bodies in the Solar System are depleted in some of the more volatile rock-forming elements relative to chondrites 1 . In general, the more volatile the element, the greater its affinity for gas rather than rock, and the more depleted it is in these bodies. The origin of the volatility trend is hotly debated [2] [3] [4] , but two studies now suggest an answer to this abiding geochemical question. On page 511, Hin et al. 5 demonstrate that isotope ratios of magnesium in Earth, Mars and some asteroids provide evidence for extensive evaporation of molten rock. On page 507, Norris and Wood 6 report experiments showing that Earth's concentrations of several chalco phile (sulfur-loving) elements are also best explained by the partial melting and evaporation of rock. Both studies propose energetic collisions between planetesimals -the asteroid-sized rocky precursors to planets -as the likely cause of rock melting and evaporation.
During their formation, Earth and many 
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